Based on our findings, crizotinib might be useful for this group of patients with lung cancers harboring wild-type EGFR. In summary, combined use of EGFR-TKI with a MET inhibitor or inhibition of downstream signaling molecules, such as PI3K or MEK, might be a better therapeutic alternative for at least a part of advanced lung cancer patients. Here, MET is linked to lung cancer.